Should I buy or sell Hologic stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last twelve months. There are currently 6 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HOLX shares. View HOLX analyst ratings or view top-rated stocks .

What is Hologic's stock price target for 2024?

13 analysts have issued 1-year target prices for Hologic's shares. Their HOLX share price targets range from $72.00 to $105.00. On average, they anticipate the company's share price to reach $86.58 in the next year. This suggests a possible upside of 22.7% from the stock's current price. View analysts price targets for HOLX or view top-rated stocks among Wall Street analysts .

How have HOLX shares performed in 2023?

Hologic's stock was trading at $74.81 at the beginning of the year. Since then, HOLX shares have decreased by 5.7% and is now trading at $70.58. View the best growth stocks for 2023 here .

Are investors shorting Hologic?

Hologic saw a decline in short interest in November. As of November 15th, there was short interest totaling 6,180,000 shares, a decline of 13.4% from the October 31st total of 7,140,000 shares. Based on an average trading volume of 1,780,000 shares, the days-to-cover ratio is presently 3.5 days. Currently, 2.6% of the company's shares are sold short. View Hologic's Short Interest .

When is Hologic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 7th 2024. View our HOLX earnings forecast .

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) announced its quarterly earnings data on Thursday, November, 9th. The medical equipment provider reported $0.89 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.05. The medical equipment provider earned $945.30 million during the quarter, compared to the consensus estimate of $940 million. Hologic had a net margin of 11.31% and a trailing twelve-month return on equity of 19.12%. The company's revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.82 EPS. Read the conference call transcript .

What ETFs hold Hologic's stock?

ETFs with the largest weight of Hologic (NASDAQ:HOLX) stock in their portfolio include OneAscent Large Cap Core ETF (OALC) , VictoryShares THB Mid Cap ESG ETF (MDCP) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) , VictoryShares Nasdaq Next 50 ETF (QQQN) , SEI Enhanced U.S. Large Cap Quality Factor ETF (SEIQ) , Fidelity Women's Leadership ETF (FDWM) , First Trust Indxx Medical Devices ETF (MDEV) and iShares U.S. Medical Devices ETF (IHI) .

What guidance has Hologic issued on next quarter's earnings?

Hologic issued an update on its FY24 earnings guidance on Thursday, November, 9th. The company provided earnings per share (EPS) guidance of $3.90 to $4.10 for the period, compared to the consensus EPS estimate of $3.92. The company issued revenue guidance of $3.920 billion to $4.020 billion, compared to the consensus revenue estimate of $4.06 billion.

What is Steve MacMillan's approval rating as Hologic's CEO?

447 employees have rated Hologic Chief Executive Officer Steve MacMillan on Glassdoor.com . Steve MacMillan has an approval rating of 79% among the company's employees. 81.0% of employees surveyed would recommend working at Hologic to a friend.

What other stocks do shareholders of Hologic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include AbbVie (ABBV) , NVIDIA (NVDA) , Johnson & Johnson (JNJ) , Alibaba Group (BABA) , Walt Disney (DIS) , PayPal (PYPL) , Advanced Micro Devices (AMD) , CVS Health (CVS) , Pfizer (PFE) and Abbott Laboratories (ABT) .

Who are Hologic's major shareholders?

Hologic's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (2.41%), Victory Capital Management Inc. (1.98%), Parnassus Investments LLC (1.32%), Ameriprise Financial Inc. (1.28%), Northern Trust Corp (1.19%) and Invesco Ltd. (1.04%). Insiders that own company stock include Benjamin Jordan Cohn , Essex D Mitchell , Jan Verstreken , John M Griffin , Karleen Marie Oberton , Kevin R Thornal , Scott T Garrett , Sean S Daugherty and Sean S Daugherty . View institutional ownership trends .

How do I buy shares of Hologic?

Shares of HOLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Hologic have any subsidiaries?

The following companies are subsidiares of Hologic: Acessa Health, Acessa Health Inc., Beijing Hologic Technology Co. Ltd., Benassar Diagnostica-Equipamientos Medicos Unipessoal Lda., BioLucent, BioLucent LLC, Bioptics Inc., Biotheranostics Inc, Biotheranostics Inc., Bolder Surgical, Cynosure, Cytyc, Cytyc Corporation, Cytyc Prenatal Products Corp., Cytyc Surgical Products LLC, Diagenode Co. Ltd., Diagenode LLC, Diagenode SA, Diagenode SA., Diagenode SPA, Direct Radiography Corp., Emsor Sociedad de responsabilidad limitada, Faxitron Bioptics, Faxitron Bioptics LLC, Focal Therapeutics, Gen-Probe, Gen-Probe Incorporated, Gen-Probe Prodesse Inc., Gen-Probe Sales & Service Inc., Genewave SAS, Health Beacons Inc, Health Beacons Inc., Hologic (Australia & New Zealand) Pty Ltd., Hologic (MA) LLC, Hologic (Shanghai) Medical Supplies Co. Ltd., Hologic ASE LLC, Hologic Asia Limited, Hologic Asia Pacific Limited, Hologic Austria GmbH, Hologic BV, Hologic Bermuda Limited, Hologic Canada ULC, Hologic Caribbean (Barbados) SRL, Hologic Denmark ApS, Hologic Deutschland GmbH, Hologic Espana S.A., Hologic Finance Ltd., Hologic France SARL, Hologic GGO 2 LLC, Hologic GGO 3 LLP, Hologic GGO 4 LTD, Hologic Global Holding LTD, Hologic HUB LTD, Hologic Hitec-Imaging, Hologic Hitec-Imaging GmbH, Hologic Holdings Limited, Hologic IP LTD, Hologic Iberia S.L., Hologic India LLP, Hologic International Holdings B.V., Hologic Ireland Limited, Hologic Italia S.r.l., Hologic Japan KK, Hologic Latin America (Servicos Em Marketing E Negocios) Ltda., Hologic Ltd., Hologic Malaysia SDN. BHD., Hologic Medical Technologies (Beijing) Co. Ltd., Hologic Medicor GmbH, Hologic Medicor Suisse GmbH, Hologic Netherlands B.V., Hologic Nordic Holdings Oy, Hologic Singapore Pte. Ltd, Hologic Suisse SA, Hologic Surgical Products Costa Rica S.R.L., Hologic Sweden AB, Hologic Taiwan Ltd., Hologic UK Finance Ltd., Hologic US Finance Co LLC, Interlace Medical, Mobidiag Oy, Mobidiag Oy., Mobidiag UK Ltd., NXT-Dx SCRL, Navigation Three Limited, R2 Technology, Sentinelle Medical, Somatex (HK) Limited, Somatex Medical Technologies GmbH, Somatex Medical Technologies GmbH., Somatex USA Inc., SuperSonic Imagine (Shanghai) Medical Devices Co. Ltd., SuperSonic Imagine GmbH, SuperSonic Imagine HK Ltd, SuperSonic Imagine Ltd, SuperSonic Imagine SA, SuperSonic Imagine Srl, Suros Surgical Systems, Suros Surgical Systems Inc., TCT International, TCT International Co. Ltd., Third Wave Technologies, and Tridaho LLC. Read More

Hologic Stock Price, News & Analysis (NASDAQ:HOLX)

$70.58

-0.57 (-0.80%)

(As of 12/4/2023 ET)

Compare

Today's Range: $70.05
▼
$71.30
50-Day Range: $65.11
▼
$72.63
52-Week Range: $64.02
▼
$87.88

Volume: 2.00 million shs
Average Volume: 1.66 million shs
Market Capitalization: $16.94 billion

P/E Ratio: 38.57
Dividend Yield: N/A
Price Target: $86.58

Hologic MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.54 Rating Score
Upside/Downside: 22.7% Upside
$86.58 Price Target
Short Interest: Healthy
2.61% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.44
Upright™ Environmental Score
News Sentiment: 0.89
Based on 9 Articles This Week
Insider Trading: Selling Shares
$538,875 Sold Last Quarter
Proj. Earnings Growth: 8.02%
From $3.99 to $4.31 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.99 out of 5 stars

Medical Sector

28th out of 952 stocks

X - Ray Apparatus & Tubes Industry

1st out of 6 stocks

3.3

Analyst's Opinion

Consensus Rating
Hologic has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 7 buy ratings, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $86.58, Hologic has a forecasted upside of 22.7% from its current price of $70.58.
Amount of Analyst Coverage
Hologic has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
2.61% of the float of Hologic has been sold short.
Short Interest Ratio / Days to Cover
Hologic has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Hologic has recently decreased by 13.45%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Hologic does not currently pay a dividend.
Dividend Growth
Hologic does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Hologic has received a 65.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "HPV test kits", "Ultrasound machines", "Private breast cancer diagnostics services", "3d ultrasound imaging software", "Blood concentration quick tests", and "Virology laboratory services for research" products. See details.
Environmental Sustainability
The Environmental Impact score for Hologic is -1.44.

3.3

News and Social Media Coverage

News Sentiment
Hologic has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Hologic this week, compared to 6 articles on an average week.
Search Interest
Only 3 people have searched for HOLX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
MarketBeat Follows
2 people have added Hologic to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hologic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $538,875.00 in company stock.
Percentage Held by Insiders
Only 1.66% of the stock of Hologic is held by insiders.
Percentage Held by Institutions
92.64% of the stock of Hologic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Hologic are expected to grow by 8.02% in the coming year, from $3.99 to $4.31 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Hologic is 38.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.43.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hologic is 38.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 117.87.
Price to Earnings Growth Ratio
Hologic has a PEG Ratio of 2.31. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Hologic has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Hologic Stock (NASDAQ:HOLX)

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalovirus; Aptima BV and Aptima CV/TV assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology, and treatment, such as 2D and 3D digital mammography systems, image analytics software, reading workstations, ultrasound imaging, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and ultrasound and connectivity solutions, as well as breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology in the uterus; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; and the CoolSeal portfolio that includes bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

HOLX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HOLX Stock News Headlines

November 28, 2023 | finance.yahoo.com

30 Countries with the Lowest Median Age in the World

November 28, 2023 | americanbankingnews.com

Hologic (NASDAQ:HOLX) Rating Lowered to Hold at StockNews.com

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 26, 2023 | americanbankingnews.com

Hologic, Inc. (NASDAQ:HOLX) Insider Sells $538,875.00 in Stock

November 26, 2023 | americanbankingnews.com

Essex D. Mitchell Sells 7,500 Shares of Hologic, Inc. (NASDAQ:HOLX) Stock

November 25, 2023 | finance.yahoo.com

Insider Sell Alert: Div. President, GYN Surgical Essex Mitchell Sells 7,500 Shares of Hologic ...

November 24, 2023 | finance.yahoo.com

Hologic to Showcase Developments in Next-Generation AI Solutions at RSNA 2023

November 22, 2023 | finance.yahoo.com

Decoding Hologic Inc (HOLX): A Strategic SWOT Insight

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 21, 2023 | seekingalpha.com

Hologic: Navigating The Covid Cliff

November 21, 2023 | finance.yahoo.com

Hologic to Webcast Presentation at the 6th Annual Evercore ISI HealthCONx Conference

November 17, 2023 | markets.businessinsider.com

Hologic Stock’s Potential Upside and Risks: An Analysis of Market Opportunities and Financial Positioning

November 14, 2023 | finance.yahoo.com

Steven Cohen's Point72 Asset Management Adjusts Portfolio, Notably Reduces Adobe Stake

November 11, 2023 | msn.com

Hologic CEO on Q4 earnings beat, $4 billion cash on balance sheet

November 11, 2023 | msn.com

Hologic gains as Q4 results cite ex-COVID growth

November 10, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Vera Therapeutics (VERA) and Hologic (HOLX)